OA10114A - New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) - Google Patents

New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) Download PDF

Info

Publication number
OA10114A
OA10114A OA60588A OA60588A OA10114A OA 10114 A OA10114 A OA 10114A OA 60588 A OA60588 A OA 60588A OA 60588 A OA60588 A OA 60588A OA 10114 A OA10114 A OA 10114A
Authority
OA
OAPI
Prior art keywords
urea
bis
methylpyridin
methylthio
heptyl
Prior art date
Application number
OA60588A
Other languages
English (en)
Inventor
Ernest S Hamanaka
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10114A publication Critical patent/OA10114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
OA60588A 1992-05-28 1994-11-28 New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) OA10114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89005092A 1992-05-28 1992-05-28

Publications (1)

Publication Number Publication Date
OA10114A true OA10114A (en) 1996-12-18

Family

ID=25396173

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60588A OA10114A (en) 1992-05-28 1994-11-28 New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat)

Country Status (23)

Country Link
US (1) US6001860A (fr)
EP (1) EP0642498A1 (fr)
JP (1) JPH07503737A (fr)
KR (1) KR950701621A (fr)
CN (1) CN1080919A (fr)
AU (1) AU4028393A (fr)
BG (1) BG99188A (fr)
BR (1) BR9306421A (fr)
CA (1) CA2134359C (fr)
FI (1) FI932423A7 (fr)
HR (1) HRP930931A2 (fr)
HU (1) HUT64303A (fr)
IL (1) IL105756A0 (fr)
IS (1) IS4023A (fr)
MA (1) MA22896A1 (fr)
MX (1) MX9303100A (fr)
OA (1) OA10114A (fr)
PL (1) PL299082A1 (fr)
RU (1) RU94046149A (fr)
SK (1) SK142694A3 (fr)
UY (1) UY23589A1 (fr)
WO (1) WO1993024458A1 (fr)
YU (1) YU37193A (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94046149A (ru) * 1992-05-28 1996-11-27 Пфайзер Инк. (US) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
IL109568A0 (en) * 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES2076865B1 (es) * 1993-07-05 1996-08-01 Pfizer Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat).
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
AU3577995A (en) * 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
CZ272296A3 (en) 1995-09-18 1997-04-16 Sankyo Co Novel derivatives of urea exhibiting acat inhibition activity, their preparation and therapeutic and prophylactic application
DE69734773T2 (de) 1996-08-22 2006-07-20 Warner-Lambert Company Llc Nicht-peptidische Bombesin-Rezeptor-Antagonisten
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
AU1367599A (en) * 1997-11-03 1999-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
EP1473292A1 (fr) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Composes heterocycliques aromatiques convenant en tant qu'agents anti-inflammatoires
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
EP2298311B1 (fr) 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
MXPA01008440A (es) 1999-02-22 2002-04-24 Boehringer Ingelheim Pharma Derivados heterociclicos policiclos como agentes anti-inflamatorios..
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
WO2000055152A1 (fr) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Composes aromatiques heterocycliques utilises en tant qu'agents anti-inflammatoires
CA2374737C (fr) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Nouveau procede de synthese de composes d'uree a substitution heteroaryle
ES2292488T3 (es) 1999-11-16 2008-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de la urea, como agentes antiinflamatorios.
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
HUP0301010A3 (en) 2000-02-02 2005-03-29 Warner Lambert Co Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders and pharmaceutical compositions containing them
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
MXPA03010724A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
KR101018318B1 (ko) * 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
EP1480973B1 (fr) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. Composes de cycloalkyle uree benzofusionnes a disubstitution en position 1,4 utiles dans le traitement de maladies mediees par la cytokine
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
CA2744893A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Derives d'arylcarbonyle servant d'activateurs de glucokinase
US7399866B2 (en) * 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP2009500378A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
JP4960355B2 (ja) * 2005-07-14 2012-06-27 ノボ・ノルデイスク・エー／エス ウレア型グルコキナーゼ活性化剤
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
WO2007075377A2 (fr) * 2005-12-15 2007-07-05 Cytokinetics, Inc. Entites chimiques, compositions et procedes
WO2007078815A2 (fr) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Entites chimiques, compositions et methodes
WO2007078839A2 (fr) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Composes, compositions et methodes
JP5015496B2 (ja) * 2006-06-01 2012-08-29 ルネサスエレクトロニクス株式会社 固体撮像装置、撮像方法および撮像システム
CA2661898A1 (fr) * 2006-08-25 2008-02-28 Abbott Laboratories Derives d'indazole inhibant trpv1, et leur utilisation
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
CN101827585A (zh) * 2007-10-19 2010-09-08 雅培股份有限两合公司 含有n-芳基脲基化合物的固态分散体产品
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
US8232411B2 (en) * 2008-03-20 2012-07-31 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN103172543B (zh) * 2011-12-21 2016-02-10 中国科学院上海药物研究所 一种脲类化合物、制备方法及其用途
TWI539385B (zh) 2015-01-28 2016-06-21 金佶科技股份有限公司 光動能指紋辨識模組
CA3093025A1 (fr) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Utilisations therapeutiques d'activateurs de glucokinase en combinaison avec de l'insuline ou des analogues d'insuline
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
MX2023014819A (es) 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426031A (en) * 1967-01-19 1969-02-04 Dow Chemical Co 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4751026A (en) * 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) * 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja) * 1986-07-11 1988-02-01 ワ−ナ−−ランバ−ト・コンパニ− Ω−（置換フエニルオキシ）−アルカン酸のアリ−ル−およびアラルキルアミド
US4716175A (en) * 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US4743605A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
IE61716B1 (en) * 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US5015644A (en) * 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
EP0297610B1 (fr) * 1987-07-02 1991-03-13 Warner-Lambert Company N-[(phényl 2,6-substitué)urées]-carbamates inhibiteurs de l'acyl-co-enzyme A:cholestérol-acyltransférase
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5116848A (en) * 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US5155127A (en) * 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) * 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
PT93158A (pt) * 1989-02-17 1990-08-31 Warner Lambert Co Processo para a preparacao de compostos de ureia trissubstituidos e de composicoes farmaceuticas que os contem
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
AU629376B2 (en) * 1989-08-04 1992-10-01 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
WO1991004027A1 (fr) * 1989-09-15 1991-04-04 Pfizer Inc. Nouveaux derives de n-aryle de n-heteroarylamide et d'uree en tant qu'inhibiteurs d'acyl coenzyme a: cholesterol acyl transferase
TW205037B (fr) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) * 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
EP0447116B1 (fr) * 1990-03-12 1994-12-14 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de l'urée, leur préparation, et compositions pharmaceutiques les contenant
AU7440691A (en) * 1990-03-12 1991-10-10 Yamanouchi Pharmaceutical Co., Ltd. Monourea derivative and its salt
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
RU94046149A (ru) * 1992-05-28 1996-11-27 Пфайзер Инк. (US) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)

Also Published As

Publication number Publication date
CN1080919A (zh) 1994-01-19
MX9303100A (es) 1994-06-30
HRP930931A2 (en) 1997-06-30
KR950701621A (ko) 1995-04-28
SK142694A3 (en) 1995-06-07
EP0642498A1 (fr) 1995-03-15
PL299082A1 (en) 1994-04-05
IL105756A0 (en) 1993-09-22
JPH07503737A (ja) 1995-04-20
US6001860A (en) 1999-12-14
HUT64303A (en) 1993-12-28
YU37193A (sh) 1997-07-31
MA22896A1 (fr) 1993-12-31
FI932423L (fi) 1993-11-29
CA2134359C (fr) 1997-07-01
BG99188A (bg) 1995-07-28
RU94046149A (ru) 1996-11-27
IS4023A (is) 1993-11-29
WO1993024458A1 (fr) 1993-12-09
BR9306421A (pt) 1998-09-15
FI932423A7 (fi) 1993-11-29
CA2134359A1 (fr) 1993-12-09
UY23589A1 (es) 1993-11-15
HU9301552D0 (en) 1993-09-28
FI932423A0 (fi) 1993-05-27
AU4028393A (en) 1993-12-30

Similar Documents

Publication Publication Date Title
US6001860A (en) N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT)
EP0609960B1 (fr) Dérivés de N-hétéroarylamide comme inhibiteurs d'acyl coenzym A: cholestérol-acyl-transferase
US5362878A (en) Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US5147876A (en) 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, their pharmaceutically acceptable salts, pharmaceutical compositions containing same and their use in the treatment of neurological diseases
EP3594221B1 (fr) Antagoniste du récepteur gpr84 et son utilisation
EP0497564A1 (fr) Benzamides
KR100239800B1 (ko) 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
EP0468971A1 (fr) Derives nouveaux de benzimidazole
AU682768B2 (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
EP0623112B1 (fr) Dérivés de 4-phenyl-(heteroarylureido)-1,2-dihydro-2-oxoquinoleine utilises comme agents antihypercholesterolemie et antiatherosclerose
EP0590094A1 (fr) Derives de 4-aryle-3-(heteroarylureido)quinoline
WO1998006401A1 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation desdits composes
HU202506B (en) Process for producing benzoxazolone derivatives
EP1019376A1 (fr) Derives de pyridone, leur preparation et leur utilisation comme intermediaires de synthese
DK170334B1 (da) 2-Pyridonderivater og tautomere og syreadditionssalte deraf, fremgangsmåde til fremstilling deraf, farmaceutiske præparater med indhold deraf samt anvendelse af 2-pyridonderivaterne til fremstilling af farmaceutiske præparater
US5264435A (en) Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
KR20000065865A (ko) 4,5-다이아미노 피리미딘 유도체 및 이의 제조방법
EP0511297A1 (fr) Derives d'oxathiane